ORASURE TECHNOLOGIES INCOSUREarnings & Financial Report
OraSure Technologies, Inc. is a Bethlehem, Pennsylvania–based company in the medical device industry. Their products include diagnostic testing kits. The company had recently developed OraQuick testing kit, the first over-the-counter home HIV test.
Revenue
$54.3M
Gross Profit
$24.7M
Operating Profit
$-2.7M
Net Profit
$-615.0K
Gross Margin
45.4%
Operating Margin
-5.0%
Net Margin
-1.1%
YoY Growth
-36.4%
EPS
$-0.01
ORASURE TECHNOLOGIES INC Q2 FY2024 Financial Summary
ORASURE TECHNOLOGIES INC reported revenue of $54.3M (down 36.4% YoY) for Q2 FY2024, with a net profit of $-615.0K (up 87.2% YoY) (-1.1% margin). Cost of goods sold was $29.6M, operating expenses totaled $27.4M.
Key Financial Metrics
| Total Revenue | $54.3M |
|---|---|
| Net Profit | $-615.0K |
| Gross Margin | 45.4% |
| Operating Margin | -5.0% |
| Report Period | Q2 FY2024 |
ORASURE TECHNOLOGIES INC Annual Revenue by Year
ORASURE TECHNOLOGIES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $115.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $115.0M |
| 2024 | $185.8M |
| 2023 | $405.5M |
| 2022 | $387.5M |
ORASURE TECHNOLOGIES INC Quarterly Revenue & Net Profit History
ORASURE TECHNOLOGIES INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $26.8M | -28.5% | $-19.3M | -72.1% |
| Q3 FY2025 | $27.1M | -32.1% | $-13.7M | -50.6% |
| Q2 FY2025 | $31.2M | -42.5% | $-19.7M | -63.0% |
| Q1 FY2025 | $29.9M | -44.7% | $-16.0M | -53.6% |
| Q4 FY2024 | $37.4M | -50.7% | $-10.8M | -28.8% |
| Q3 FY2024 | $39.9M | -55.2% | $-4.5M | -11.3% |
| Q2 FY2024 | $54.3M | -36.4% | $-615.0K | -1.1% |
| Q1 FY2024 | $54.1M | -65.1% | $-3.6M | -6.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $54.1M | $54.3M | $39.9M | $37.4M | $29.9M | $31.2M | $27.1M | $26.8M |
| YoY Growth | -65.1% | -36.4% | -55.2% | -50.7% | -44.7% | -42.5% | -32.1% | -28.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $467.6M | $466.3M | $464.1M | $479.7M | $457.6M | $445.0M | $423.1M | $403.2M |
| Liabilities | $41.3M | $40.5M | $38.5M | $69.3M | $61.3M | $64.3M | $61.1M | $62.3M |
| Equity | $426.3M | $425.8M | $425.6M | $410.3M | $396.3M | $380.7M | $362.0M | $340.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $6.7M | $7.8M | $12.7M | $109000 | $-19.7M | $-10.2M | $-10.1M | $-9.0M |